Joshi S, Young W L, Pile-Spellman J, Fogarty-Mack P, Sciacca R R, Hacein-Bey L, Duong H, Vulliemoz Y, Ostapkovich N, Jackson T
Department of Anesthesiology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
Stroke. 1997 Jun;28(6):1115-22. doi: 10.1161/01.str.28.6.1115.
The mechanism of adaptation to chronic cerebral hypotension in normal brain adjacent to cerebral arteriovenous malformations (AVMs) is unknown. To clarify these mechanisms, we performed cerebral blood flow (CBF) studies in structurally and functionally normal vascular territories during 53 distal cerebral angiographic procedures in 37 patients with AVMs.
CBF was measured using the superselective intra-arterial 133Xe method before and after a 3-minute infusion of either verapamil (1 mg.min-1, n = 23), acetylcholine (1.33 micrograms.kg-1.min-1, n = 7), nitroprusside (0.5 microgram.kg-1.min-1, n = 16) or nitroglycerin (0.5 microgram.kg-1.min-1, n = 7).
Mean +/- SD systemic (76 +/- 13 mm Hg) and distal cerebral arterial (55 +/- 16 mm Hg; range, 20 to 97 mm Hg) pressures were not different among groups. Verapamil increased CBF (45 +/- 12 to 65 +/- 21 mL.100 g-1.min-1, P < .001). There was no effect of acetylcholine (no change [46 +/- 9 to 46 +/- 9 mL.100 g-1.min-1], NS) or nitroglycerin (36 +/- 14 to 36 +/- 13 mL.100 g-1.min-1, NS). Nitroprusside decreased CBF (40 +/- 12 to 31 +/- 11 mL.100 g-1.min-1, P < .001). The percent change in CBF after drug administration was proportional to cerebral arterial pressure for verapamil only (r = .57, P = .0051).
When infused intra-arterially in clinically relevant doses in both hypotensive and normotensive normal vascular territories remote from an AVM nidus, calcium channel blockade caused vasodilation, but there was an absence of response to nitric oxide-mediated vasodilators. These data suggest that (1) the nitric oxide pathway probably is not involved in the adaptation to chronic cerebral hypotension in AVM patients and (2) if our findings in vessels remote from or contralateral to the AVM are applicable to vessels of patients with other forms of cerebrovascular disease, clinically relevant doses of intra-arterial nitrovasodilators may not be useful in the manipulation of cerebrovascular resistance.
大脑动静脉畸形(AVM)周围正常脑组织适应慢性脑低血压的机制尚不清楚。为阐明这些机制,我们在37例AVM患者的53次远端脑血管造影过程中,对结构和功能正常的血管区域进行了脑血流量(CBF)研究。
采用超选择性动脉内133Xe法在静脉注射维拉帕米(1mg·min-1,n = 23)、乙酰胆碱(1.33μg·kg-1·min-1,n = 7)、硝普钠(0.5μg·kg-1·min-1,n = 16)或硝酸甘油(0.5μg·kg-1·min-1,n = 7)3分钟前后测量CBF。
各组间平均±标准差的全身血压(76±13mmHg)和远端脑动脉血压(55±16mmHg;范围20至97mmHg)无差异。维拉帕米使CBF增加(45±12至65±21mL·100g-1·min-1,P <.001)。乙酰胆碱(无变化[46±9至46±9mL·100g-1·min-1],无统计学意义)或硝酸甘油(36±14至36±13mL·100g-1·min-1,无统计学意义)无作用。硝普钠使CBF降低(40±12至31±11mL·100g-1·min-1,P <.001)。仅维拉帕米给药后CBF的变化百分比与脑动脉压成比例(r =.57,P =.0051)。
在远离AVM病灶的低血压和正常血压的正常血管区域,以临床相关剂量动脉内注射时,钙通道阻滞剂引起血管舒张,但对一氧化氮介导的血管舒张剂无反应。这些数据表明:(1)一氧化氮途径可能不参与AVM患者对慢性脑低血压的适应;(2)如果我们在远离AVM或AVM对侧血管的研究结果适用于其他形式脑血管疾病患者的血管,临床相关剂量的动脉内硝基血管舒张剂可能无助于调节脑血管阻力。